|

Eflornithine Clinical Trials

3 actively recruiting trials across 2 locations

No change since June 2026

Also known as: Alpha-Difluoromethylornithine, DFMO, Difluoromethylornithine, Difluromethylornithine, difluoromethylornithine

Pipeline

Early 1: 1Phase 2: 1Phase 1/2: 1

Top Sponsors

  • Mayo Clinic2
  • Milton S. Hershey Medical Center1

Indications

  • Cancer3
  • Malignant Glioma2
  • Ewing Sarcoma Metastatic1
  • Diffuse Glioma1
  • Astrocytoma, IDH-Mutant, Grade 41

Rochester, Minnesota2 trials

Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma

Mayo Clinic in Rochester

Early 1
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

Mayo Clinic in Rochester

Phase 1/2

Tampa, Florida1 trial

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

St. Joseph's Children's Hospital

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.